Global Antibiotic R&D Partnership (GARDP)
Raphael Tissot is a seasoned finance professional with extensive experience in various roles within the field. Currently serving as a Senior Finance Officer at the Global Antibiotic R&D Partnership (GARDP) since January 2018, Raphael has previously held finance-related positions at the Drugs for Neglected Diseases initiative (DNDi) from June 2015 to July 2019, where responsibilities included managing the expansion project of the headquarters. Other notable experiences include project management internships focused on social entrepreneurship and marketing roles that involved communication campaigns and supplier management. Raphael's educational background includes a Master's degree in International Management, a Bachelor's degree in Team Management and Quality, a Technical University Diploma in Marketing Techniques, and an Accounting certificate.
Global Antibiotic R&D Partnership (GARDP)
The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit organization that develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health, and makes them accessible to the people who need them. It puts public health needs at the centre of antibiotic drug development to address both the immediate antimicrobial resistance (AMR) crisis and to ensure people continue to get access to essential antibiotics for generations to come. GARDP works through a global network including Brazil, India, Japan, and South Africa for antibiotic development and access. Its work is made possible by essential funding from donors and collaboration with over 100 R&D and access partners in over 20 countries. GARDP was created by the World Health Organization and the Drugs for Neglected Diseases initiative (DNDi) in 2016 and legally registered as the GARDP Foundation in Geneva, Switzerland in 2018. www.gardp.org